Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Description

This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)

Conditions

Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is being done to test a new communication tool for people with ovarian cancer, caregivers, and clinicians. The name of the intervention in this research study is: -Collaborative Agenda-Setting Intervention (CASI)

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

Condition
Ovarian Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * At least 18 years old
  • * Able to speak, understand, and respond to questions written in English
  • * Willing to be audio recorded
  • * Have a diagnosis of advanced ovarian cancer (defined as stage III, stage IV, or recurrent disease)
  • * Be under the care of a participating clinician dyad
  • * Be scheduled for chemotherapy during the recruitment period
  • * Be signed up or willing to sign up for Patient Gateway
  • * Age of \<18 years
  • * Unable to consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Rachel Pozzar, PhD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

2025-12-31